NCT06020235尚未招募2 期
A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Antimicrobial Efficacy of Topically Once or Twice Daily Applied Bisphosphocin® Nu-3 Gel At 5% and 10% Concentrations to Infected Diabetic Foot Ulcers (iDFU)
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 入组人数
- 60
- 主要终点
- Safety
研究概览
简要总结
The goal of this clinical trial is to test a topical drug in patients with mild infections of their diabetic foot ulcer. The main questions it aims to answer are:
What strength does the drug need to be in order to make the infection better? How frequently does the drug need to be applied in order to make the infection better? Participants will be asked to apply the medicine on their foot ulcer twice a day for 2 weeks and remain off of that foot during that time.
Participants will receive the medication either once a day or twice a day, in either a 5% or 10% gel, or placebo.
Researchers will compare the 5% and 10% gels to placebo to see if the infection improves.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male and female subjects ≥18 years of age.
- •Voluntary written informed consent, including information about the provisions of the Health Insurance Portability and accountability act (HIPAA) as applicable.
- •Non-hospitalized ambulatory subjects diagnosed with diabetes mellitus, Type I or II per ADA criteria with signs of a localized mild foot infection as defined by the IDSA infection severity criteria (Lipsky,2012)
- •a. the presence of purulent drainage or at least two of the following criteria: i. erythema, ii. warmth, iii. pain or tenderness, iv. edema, or v. induration (The diagnosis of mild infection must be confirmed immediately following debridement at Baseline).
- •The target ulcer is classified as a grade 1 ulcer according to the Wagner Scale (Wagner 1979). The ulcer is a superficial, full-thickness ulcer limited to the dermis, not extending to the subcutis. Target ulcer is >1 cm2 and <12 cm2 post debridement at baseline and must be no higher than the ankle, on or below the malleolus (ankle bone) with ≥50% below the malleolus.
- •Adequate vascular perfusion as evidenced by one of the following:
- •Dorsal transcutaneous oxygen measurement (TCOM) or a skin perfusion pressure (SPP) measurement of ≥ 40 mmHg
- •Ankle Branchial Index (ABI) between 0.9 and 1.3 within 3 months of Screening using the extremity with the target ulcer.
- •Arterial Doppler ultrasound evaluating for biphasic or triphasic dorsalis pedis and posterior tibial vessels at the level of the ankle or a TBI (Toe Brachial Index) of >0.
- •Subject has a caregiver who will attend the Baseline visit (V2) and/or watch the dosing and dressing demonstration video and apply wound treatment along with study dressings for the study duration.
- •Must meet one of the following criteria:
- •a. Female subjects of Non-Child-Bearing Potential i. Postmenopausal for at least 1 year ii. Surgically sterilized (i.e., hysterectomy or bilateral oophorectomy more than 3 months prior to Screening) iii. Bilateral tube ligation > 6 months prior to screening iv. A negative serum β-hCG pregnancy test at screening and no breastfeeding after the administration of the study drug.
- •b. Male subjects of Non-Childbearing Potential defined as: i. Vasectomized subjects for > 6 months prior to Screening ii. Those diagnosed as sterile by a physician. c. Females and Males of Childbearing Potential who practice an acceptable method of contraception defined as the i. Use of any form of hormonal contraceptive ii. Use of a barrier method with spermicide, condoms, intrauterine device, iii. Abstinence from sexual intercourse starting at least 60 days prior to Screening and continuing at least 14 days following the last treatment.
- •Subjects must be willing to undergo all clinical investigation-related procedures, attend all required visits, and cooperate fully with the investigator and site personnel.
- •Subject must be willing to wear offloading RCW, if necessary, throughout the duration of the clinical treatment.
- •Subject must have plain radiograph taken at screening and prior to randomization showing no evidence of bony abnormalities consistent with osteomyelitis, or gas compatible with tissue crepitus, in the affected foot.
排除标准
- •Ulceration with exposed tendon, capsule, or bone
- •IDSA-defined moderate or severe DFU infection.
- •Infected diabetic foot ulcer that is associated with local wound complication such as prosthetic materials or protruding surgical hardware.
- •> 1 infected foot ulcer
- •Subject is currently receiving topical antimicrobial treatment for a localized infection of the study ulcer and whose infection is improving in response to treatment.
- •Subject has received a systemic antibiotic within 48 hours prior to Screening.
- •Concurrent or expected to require systemic antimicrobials during the study period for any infection including diabetic foot ulcer.
- •Any subject that has active viral hepatitis (A, B, C) and/or untreated HIV/AIDS.
- •Any subject that has vascular compromise requiring surgical intervention or has undergone vascular reconstruction or angioplasty less than 1 month prior to randomization. Any planned surgical procedures during the study participation
- •eGFR <60 and/or subject on hemodialysis within 3 months prior to randomization.
- •Hemoglobin A1c (HbA1c) >12% within 3 months prior to randomization.
- •Aspartate Aminotransferase (AST, GOT) and/or Alanine Aminotransferase (ALT, GPT) >3.0 x the upper limit of normal and/or bilirubin >1.5 x the upper limit of normal within 3 months prior to randomization.
- •Acute active Charcot foot
- •Any subject that would be unable to safely monitor the infection status at home and return for scheduled visits.
- •History of immunosuppression within 3 months prior to randomization, or taking immunosuppressive agents including systemic corticosteroids, except stable daily doses of 5 mg/day or less for chronic conditions
- •Any subject with a life expectancy ≤ 6 months
- •Use of investigational drugs within 28 days prior to screening
- •Use of Aspirin® or acetylsalicylic acid containing medication (except low-dose aspirin) < 7 days before baseline,
- •Use of oral anticoagulants (e.g., warfarin, Xarelto® or comparable products).
- •History of concurrent condition that, in the Investigator's opinion, would jeopardize the safety of the subject or compliance with the protocol including known or suspected active abuse of alcohol, narcotics, or non-prescription drugs.
- •Prior randomization in this clinical trial, or a previous Bisphosphocin study
研究组 & 干预措施
5% Nu-3 gel once daily
Experimental
The 5% Nu-3 gel is applied once per day and placebo is applied once per day.
干预措施: 5% Nu-3 gel (Drug)
5% Nu-3 gel once daily
Experimental
The 5% Nu-3 gel is applied once per day and placebo is applied once per day.
干预措施: Placebo (Drug)
5% Nu-3 gel twice daily
Experimental
The 5% Nu-3 gel is applied twice per day.
干预措施: 5% Nu-3 gel (Drug)
10% Nu-3 gel once daily
Experimental
The 10% Nu-3 gel is applied once per day and placebo is applied once per day.
干预措施: 10% Nu-3 gel (Drug)
10% Nu-3 gel once daily
Experimental
The 10% Nu-3 gel is applied once per day and placebo is applied once per day.
干预措施: Placebo (Drug)
10% Nu-3 gel twice daily
Experimental
The 10% Nu-3 gel is applied twice per day.
干预措施: 10% Nu-3 gel (Drug)
Placebo
Placebo Comparator
The placebo is applied twice per day.
干预措施: Placebo (Drug)
结局指标
主要结局
Safety
时间窗: Day 0 to Day 28
Number of AEs overall and those assessed by the investigators as possibly, probably, and definitely related to the study drug; number of SAEs per patient and cohort
Efficacy
时间窗: Day 0 to Day 14
The rate of reduction in CFUs by \>=2 logs per pathogen identified as typical and highly suspicious for being the cause of the infection, in each treatment group compared to placebo group at Day 7 compared to Day 0, and Day 14 compared to Day 0.
次要结局
- Pharmacokinetics(Day 0 to Day 13)
- Treatment failure rate per treatment regimen(Day 0 to Day 14)
- Safety(Day 0 to Day 28)
研究者
相似试验
已完成
2 期
A Clinical Study to Test the Effectiveness of an Investigational Drug to Treat People That Have Major Depressive Episodes When They Have Bipolar 1 DepressionDepressive EpisodeBipolar 1 DepressionNCT03543410Sumitomo Pharma America, Inc.344
已完成
2 期
BI 655066/ABBV-066/Risankizumab Compared to Placebo in Patients With Active Psoriatic ArthritisArthritis, PsoriaticNCT02719171AbbVie185
终止
2 期
Safety and Efficacy Study of MAGE-A3 + AS-15 in Patients With Muscle-invasive Bladder Cancer After CystectomyUrinary Bladder NeoplasmsNCT01435356European Association of Urology Research Foundation83
进行中（未招募）
3 期
Study of the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of BCD-180 in Patients With Axial Spondyloarthritis (LEVENTA)Axial SpondyloarthritisNCT06333210Biocad421
已完成
2 期
MK0249 for the Symptomatic Treatment of Alzheimer's Disease (MK0249-011)Alzheimer's DiseaseNCT00420420Merck Sharp & Dohme LLC144